A Message from Management

Dr. Yuichi Tamura

Generic pharmaceuticals are expected to play an even bigger role in the world with aim of medical cost containment as well as relieving financial burden on patients. As the times have changed, not only low-price, but also high-quality and trusted generic products have been valued and needed among any other products.
 
Since the establishment of Nichi-Iko Group in 1965, we have steadily developed our business to contribute to people’s health and quality of life by manufacturing high-quality, cost-effective pharmaceuticals.  Thanks to a broad base of customers and the appreciation for our consistent corporate attitude, we have continued to be positioned as No.1 generic maker in Japan and successfully achieved a sales target of 1 billion USD in 2014.  We were the first generic maker in Japan which attained this milestone.
 
Nichi-Iko Group will continuously strive to supply “premium quality” and trusted generic products which are “made in Japan”.  More patient-friendly, more patient-choice, more high-quality. That is what we mean by “premium quality”. We strongly expect to become a company that is trusted and chosen by customers through grasping needs of customers all over the world appropriately and fulfilling them swiftly.  
 
We never cease to “Challenge the Global Market” with a spirit of challenge and are committed to become a global Top 10 leader in generic pharmaceuticals.

Mr. Hideki Tomokuni       

          Nichi-Iko, a parent company of Nichi-Iko (Thailand), has established a great presence in the Japanese market as a top generic manufacturer. Ever since its foundation on January 2014, Nichi-Iko (Thailand) Co., Ltd. has been deeply committed to obtaining approval on Nichi-Iko products and distributing them in the Thai market through daily detailing activities by our Medical Representatives and the distributor DKSH (DKLL).
           Nichi-Iko (Thailand) has established relationships of trust with medical institutions in Thailand through the supply of high quality pharmaceutical products, mainly in cardiovascular field, then more products in respiratory and cancer field to be followed by.
As we are eager to get approval of candidate products for outstandingly growing ASEAN countries, we have been not only carrying out all of our activities with local business partners Vietnam, Malaysia and Singapore, but also planning to tap into markets in the Philippines, based on the Thailand business as a hub in ASEAN.
           Nichi-Iko (Thailand) will continue supplying our high-quality and cost-effective pharmaceutical products from Nichi-Iko in Japan and Nichi-Iko‘s group company, Sagent, Pharmaceuticals in USA, to contribute to quality of life and health of our customers in Thailand, the Land of a Thousand smile.